Erratum: Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: Discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach (Journal of Medicinal Chemistry (2012) 55 (6700-6715) DOI: 10.1021/jm300411k);Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: Discovery and in vivo activity of selective pyrazolo[1,5- a ]pyrimidine inhibitors using a focused library and structure-based optimization approach

Journal of Medicinal Chemistry

Volumn 55, Issue 15, 2012, Pages 6700-6715

  Kosugi, Tomomi ^a   Mitchell, Dale R ^b   Fujino, Aiko ^a   Imai, Minoru ^a   Kambe, Mika ^a   Kobayashi, Shinji ^a   Makino, Hiroaki ^a   Matsueda, Yohei ^a   Oue, Yasuhiro ^a   Komatsu, Kanji ^a   Imaizumi, Keiichiro ^a   Sakai, Yuri ^a   Sugiura, Satoshi ^a   Takenouchi, Osami ^a   Unoki, Gen ^a   Yamakoshi, Yuko ^a   Cunliffe, Vicky ^b   Frearson, Julie ^b   Gordon, Richard ^b   John Harris, C ^b   Kalloo Hosein, Heidi ^b,c   Le, Joelle ^b,c   Patel, Gita ^b   Simpson, Donald J ^b   Sherborne, Brad ^b,d   Thomas, Peter S ^b   Suzuki, Naotaka ^a   Takimoto Kamimura, Midori ^a   Kataoka, Ken Ichiro ^a   more..

^a TEIJIN PHARMA LIMITED   (Japan)

^b BioFocus DPI   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N (2 CHLOROPHENYL) 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; 5 CHLORO N (3 CHLORO 4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; 5 N (4 AMINOCYCLOHEXYL) 7 N (3 CHLORO 4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIMIDINE 5,7 DIAMINE; 5,7 DICHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5,7 DICHLOROPYRAZOLO[1,5 A]PYRIMIDINE; 6 METHYL 7 N (2 METHYL 1,3 BENZOTHIAZOL 6 YL) 5 N (PIPERIDIN 3 YL)PYRAZOLO[1,5 A]PYRIMIDINE 5,7 DIAMINE; 7 N (4 ETHOXYPHENYL) 6 METHYL 5 N (PIPERIDIN 3 YL)PYRAZOLO[1,5 A]PYRIMIDINE 5,7 DIAMINE; 7 N [4 (2 METHOXYETHOXY)PHENYL] 6 METHYL 5 N [PIPERIDIN 3 YL]PYRAZOLO[1,5 A]PYRIMIDINE 5,7 DIAMINE; ANTIINFLAMMATORY AGENT; CYCLIN DEPENDENT KINASE 2; ENZYME INHIBITOR; ETHYL 3 [(5 CHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YL)AMINO]BENZOATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [4 (BENZYLOXY)PHENYL] 5 CHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; PYRAZOLO[1,5 A]PYRIMIDINE; TERT BUTYL 3 [[7 [[(TERT BUTOXY)CARBONYL](4 ETHOXYPHENYL) AMINO] 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 5 YL]AMINO]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 3 [[7 [[4 (BENZYLOXY)PHENYL][(TERT BUTOXY)CARBONYL]AMINO] 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 5 YL]AMINO]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL N (3 CHLORO 4 FLUOROPHENYL) N (5 CHLOROPYRAZOLO[1,5 A]PYRIMIDIN 7 YL)CARBAMATE; TERT BUTYL N (5 CHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YL) N (2 METHYL 1,3 BENZOTHIAZOL 6 YL)CARBAMATE; TERT BUTYL N (5 CHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YL) N (4 ETHOXYPHENYL)CARBAMATE; TERT BUTYL N [4 (BENZYLOXY)PHENYL] N (5 CHLORO 6 METHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 YL)CARBAMATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; IC 50; MALE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; STRUCTURE ACTIVITY RELATION;

EID: 84864960625     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013954     Document Type: Erratum

References (40)

1. Camussi, G.; Lupia, E. The future role of anti-tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis Drugs 1998, 55 (5) 613-620
2. Braun, J.; Sieper, J. Role of novel biological therapies in psoriatic arthritis: Effects on joints and skin BioDrugs 2003, 17 (3) 187-199
3. Jarvis, B.; Faulds, D. Etanercept: A review of its use in rheumatoid arthritis Drugs 1999, 57 (6) 945-966
4. Richard-Miceli, C.; Dougados, M. Tumour necrosis factor-α blockers in rheumatoid arthritis: Review of the clinical experience BioDrugs 2001, 15 (4) 251-259
5. Seymour, H. E.; Worsley, A.; Smith, J. M.; Thomas, S. H. L. Anti-TNF agents for rheumatoid arthritis Br. J. Clin. Pharmacol. 2001, 51 (3) 201-208
6. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines Prog. Med. Chem. 2001, 38, 1-60
7. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R.; Landvatter, S. W.; Strickler, J. E; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature (London) 1994, 372 (6508) 739-746
8. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate J. Med. Chem. 2002, 45, 2994-3008
9. Tamura, K.; Sudo, T.; Senftleben, U.; Dadak, A. M.; Johnson, R.; Karin, M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis Cell 2000, 102, 221
10. Adams, R. H.; Porras, A.; Alonso, G.; Jones, M.; Vintersten, K.; Panelli, S.; Valladares, A.; Perez, L.; Klein, R.; Nebreda, A. R. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development Mol. Cell 2000, 6, 109-116
11. Cohen, P. Targeting protein kinases for the development of antiinflammatory drugs Curr. Opin. Cell Biol. 2009, 317-324
12. Kotlyarov, A.; Neininger, A.; Schubert, C.; Eckert, R.; Birchmeier, C.; Volk, H.-D.; Gaestel, M. MAPKAP kinase 2 is essential for LPS induced TNF-a biosynthesis Nat. Cell Biol. 1999, 1 (2) 94-97
13. Winzen, R.; Kracht, M.; Ritter, B.; Wilhelm, A.; Chen, C.-Y. A.; Shyu, A.-B.; Muller, M.; Gaestel, M.; Resch, K.; Holtmann, H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism EMBO J. 1999, 18 (18) 4969-4980
14. Gaestel, M. MAPKAP kinases-MKs-twos company, threes a crowd Nat. Rev. Mol. Cell Biol. 2006, 7 (2) 120-130
15. Ronkina, N.; Kotlyarov, A.; Dittrich-Breiholz, O.; Kracht, M.; Hitti, E.; Milarski, K.; Askew, R.; Marusic, S.; Lin, L.-L.; Gaestel, M.; Telliez., J.-B. The Mitogen-activated Protein Kinase (MAPK)-Activated Protein Kinases MK2 and MK3 Cooperate in Stimulation of Tumor Necrosis Factor Biosynthesis and Stabilization of p38 MAPK Mol. Cell. Biol. Jan 2007, 27, 170
16. Hegen, M.; Gaestel, M.; Nickerson-Nutter, C. L.; Lin, L. L.; Telliez, J. B. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis J. Immunol. 2006, 177, 1913-1917
17. Saklatvala, J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease Curr. Opin. Pharmacol. 2004, 4, 372-377
18. Neininger, A.; Kontoyiannis, D.; Kotlyarov, A.; Winzen, R.; Eckert, R.; Volk, H.-D.; Holtmann, H.; Kollias, G.; Gaestel, M. MK2 Targets AU-rich Elements and Regulates Biosynthesis of Tumor Necrosis Factor and Interleukin-6 Independently at Different Post-translational Levels J. Biol. Chem. 2002, 277, 3065-3068
19. Damjanov, N.; Kauffman, R. S.; Spencer-Green, G. T. Efficacy, Pharmacodynamics and Safety of VX-702, a Novel p38 MAPK Inhibitor, in Rhematoid Arthritis Arthritis Rheum. 2009, 5, 1232-1241
20. Clark, A. R.; Dean, J. L. E.; Saklatvala, J. The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese Arthritis Rheum. 2009, 5, 3513-3514
21. Anderson, D. R.; Hegde, S.; Reinhard, E.; Gomez, L.; Vernier, W. F.; Lee, L.; Liu, S.; Sambandam, A.; Snider, P. A.; Masih, L. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2) Bioorg. Med. Chem. Lett. 2005, 15, 1587-1590
22. Trujillo, J. I.; Meyers, M. J.; Anderson, D. R.; Hegde, S.; Mahoney, M. W.; Vernier, W. F.; Buchler, I. P.; Wu, K. K.; Yang, S.; Hartmann, S. J.; Reitz, D. B. Novel tetrahydro-β-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2) Bioorg. Med. Chem. Lett. 2007, 17, 4657-4663
23. Anderson, D. R.; Meyers, M. J.; Vernier, W. F.; Mahoney, M. W.; Kurumbail, R. G.; Caspers, N.; Poda, G. I.; Schindler, J. F.; Reitz, D. B.; Mourey, R. J. Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2) J. Med. Chem. 2007, 50, 2647-2654
24. Wu, J.-P.; Wang, J.; Abeywardane, A.; Andersen, D.; Emmanuel, M.; Gautschi, E.; Goldberg, D. R.; Kashem, M. A.; Lukas, S.; Mao, W.; Martin, L.; Morwick, T.; Moss, N.; Pargelis, C.; Patel, U. R.; Patnaude, L.; Peet, G. W.; Skow, D.; Snow, R. J.; Ward, Y.; Werneburg, B.; White, A. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4664-4669
25. Goldberg, D. R.; Choi, Y.; Cogan, D.; Corson, M.; DeLeon, R.; Gao, A.; Gruenbaum, L.; Hao, M. H.; Joseph, D.; Kashem, M. A.; Miller, C.; Moss, N.; Netherton, M. R.; Pargellis, C. P.; Pelletier, J.; Sellati, R.; Skow, D.; Torcelini, C.; Tseng, Y.-C.; Wang, J.; Watsi, R.; Werneburg, B.; Wu, J. P.; Xiong, Z. Pyrazinoindolone inhibitors of MAPKAP-K2 Bioorg. Med. Chem. Lett. 2008, 18, 938-941
26. Xiong, Z.; Gao, D. A.; Cogan, D. A.; Goldberg, M.-H. H.; Moss, N.; Pack, E.; Pargelis, C.; Skow, D.; Trieselmann, T.; Werneburg, B.; White, A. Synthesis and SAR studies of indole-based MK2 inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 1994-1999
27. Schlapbach, A.; Feifel, R.; Hawtin, S.; Heng, R.; Koch, G.; Moebitz, H.; Revesz, L.; Scheufler, C.; Velcicky, J.; Waelchli, R.; Huppertz, C. Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity Bioorg. Med. Chem. Lett. 2008, 18, 6142-6146
28. Anderson, D. R.; Meyers, M. J.; Kurumbail, R. G.; Caspers, N.; Poda, G. I.; Long, S. A.; Pierce, B. S.; Mahoney, M. W.; Mourey, R. J. Benzothiophene inhibitors of MK2. Part 1: Structure-activity relationships, assessments of selectivity and cellular potency Bioorg. Med. Chem. Lett. 2009, 19, 4878-4881
29. Anderson, D. R.; Meyers, M. J.; Kurumbail, R. G.; Caspers, N; Poda, G. I.; Long, S. A.; Pierce, B. S.; Mahoney, M. W.; Mourey, R. J.; Parikh, M. D. Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency Bioorg. Med. Chem. Lett. 2009, 19, 4882-4884
30. Schlapbach, A.; Huppertz, C. Low-molecular-weight MK2 inhibitors a tough nut to crack! Future Med. Chem. 2009, 1 (7) 1243-1257
31. Revesz, L.; Schlapbach, A.; Aichholz, R.; Feifel, R.; Hawtin, S.; Heng, R.; Hiestand, P.; Jahnke, W.; Koch, G.; Kroemer, M.; Möbitz, H.; Scheufler, C.; Velcicky, J.; Huppertz, C. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I Bioorg. Med. Chem. Lett. 2010, 20, 4715-4718
32. Revesz, L.; Schlapbach, A.; Aichholz, R.; Dawson, J.; Feifel, R.; Hawtin, S.; Littlewood-Evans, A.; Koch, G.; Kroemer, M.; Möbitz, H.; Scheufler, C.; Velcicky, J.; Huppertz, C. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II Bioorg. Med. Chem. Lett. 2010, 20, 4719-4723
33. Mourey, R. J.; Burnette, B. L.; Brustkern, S. J.; Daniels, J. S.; Hirsch, J. L.; Hood, W. F.; Meyers, M. J.; Mnich, S. J.; Pierce, B. S.; Saabye, M. J.; Schindler, J. F.; South, S. A.; Webb, E. G.; Zhang, J.; Anderson, D. R. A Benzothiophene Inhibitor of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Inhibits Tumor Necrosis Factor α Production and Has Oral Anti-Inflammatory Efficacy in Acute and Chronic Models of Inflammation J. Pharmacol. Exp. Ther. 2010, 333, 797-807
34. Kinase focused libraries from BioFocus were used. BioFocus URL: http://www.biofocus.com/
35. TRIPOS URL: http://www.tripos.com/
36. Williamson, D. S.; Parratt, M. J.; Bower, J. F.; Moore, J. D.; Richardson, C. M.; Dokurno, P; Cansfield, A. D.; Francis, G. L.; Hebdon, R. J.; Howes, R.; Jackson, P. S.; Lockie, A. M.; Murray, J. B.; Nunns, C. L.; Powles, J.; Robertson, A.; Surgenor, A. E.; Torrance, C. J. Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2 Bioorg. Med. Chem. Lett. 2005, 15, 863-867
37. Fujino, A.; Fukushima, K.; Namiki, N.; Kosugi, T.; Takimoto-Kamimura, M. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800 Acta Crystallogr. 2010, 66, 80-87
38. Diskin, R.; Engelberg, D.; Livnah, O. A Novel Lipid-binding site formed by the MAP Kinase Insert in p38α J. Mol. Biol. 2008, 375, 70-79
39. Perry, J. J. P.; Harris, R. M.; Moiani, D.; Olson, A. J.; Tainer, J. A. p38α. MAP Kinase C-Terminal Domain Binding Pocket Characterized by Crystallographic and Computational Analyses J. Mol. Biol. 2009, 391, 1-11
40. Fujino, A. Unpublished results.